Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-4
- Development stage
- Phase 1
- Lead developer
- Sanofi
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Inhalation, Intrathecal
01
Overview
Interleukin-4 (IL-4) is a pleiotropic cytokine and key regulator in humoral and adaptive immunity. It induces differentiation of naive helper T cells (Th0) to Th2 cells and stimulates activated B cell and T cell proliferation. IL-4 promotes class switching to IgE in B cells and upregulates MHC class II production. It is produced primarily by mast cells, Th2 cells, eosinophils and basophils. Overproduction of IL-4 is associated with allergic diseases such as asthma and atopic dermatitis. Therapeutically targeting or blocking the activity of interleukin-4 has been explored for conditions like atopic dermatitis and asthma; both antibody-based inhibitors (e.g., pasolizumab) and small-molecule inhibitors have been investigated[3][5][8]. Recombinant human interleukin-4 (Binetrakin) has also been studied as an immunomodulatory agent.
- Brand names
- Binetrakin
- Other names
- interleukin 4interleukin4interleukin-4IL-4IL4IL 4B-cell stimulatory factor 1BSF-1BSF1BSF 1BinetrakinLymphocyte stimulatory factor 1
02
Targets
IL-4R type I (Type I interleukin-4 receptor complex)IL-4R type II (Interleukin-4 receptor type II)
Beyond the preview
Go deeper on interleukin-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-4.